Commercial insight into the pharma and biotech sector.
EvaluatePharma and EP Vantage in the Press
August 2010
Multiple Remedies Needed To Heal Europe's Pharma Giants - Wall Street Journal, August 25, 2010 [subscription only]
"...According to...EvaluatePharma Ltd., annual R&D spending growth at the world's 10 largest firms is set to fall to 2.3% from 2009 to 2016..." more... [subscription only]
Teva Completes ratiopharm Acquisition and Becomes the Largest Euroopean Generics Company - EuroPharma Today, August 11, 2010
"Evaluate Pharma, in an analysis published in May this year, indicated that by 2016, Teva could well be one of the top-10 pharmaceutical companies in the world, ahead of more conventional big pharma companies like Bristol-Myers Squibb, Lilly and Amgen." more...
Gastroenterologists “prescribing Humira off-label for ulcerative colitis” - PharmaTimes online, August 9, 2010
"...a recent study by EvaluatePharma forecasts that by 2016 [Humira] will be the world’s top-selling drug, with sales growing 9% a year to total $10.1 billion in that year" more...
The Commercial Chemist - Chemistry World's round-up of money and molecules - Chemistry World blog, August 4, 2010
"According to pharmaceutical analysis company EvaluatePharma, two key shareholders with a combined stake of 38.9 per cent have already agreed to sell their shares to Shire." more...
Big Pharma Won't Wait in Rush for Biotech's Drugs - Wall Street Journal, August 4, 2010 [subscription only]
"...The average upfront payment for a Phase I asset was 68% higher in 2009 than a year earlier at $46 million and 39% higher at $37 million for a phase II product, according to data from research firm EvaluatePharma." more... [subscription only]
Alternative biologics set to shake up RA market - PharmaTimes online, August 3, 2010
"Second-quarter sales of Humira...rose 21.5% to $1.59 billion, Abbott reported last month, and analysts at EvaluatePharma recently forecast that it will be the world's top-selling drug by 2016..." more...
July 2010
Actos Cashes In On Avandia Safety Concerns - Pharmaceutical Technology Magazine, July 30, 2010
"Sales of [Actos] have risen from $2.8 billion in 2006 to $3.8 billion in 2008, according to EvaluatePharma." more...
The Research Revolution - Pharmiweb.com, July 19, 2010
"...according to data acquired from EvaluatePharma, the industry is set to lose up to $58bn in global sales from patent expirations in 2011, as blockbuster drugs such as Singulair (Merck), Lipitor (Pfizer) and Nexium (AstraZeneca) all lose their patents." more...
At EuroBiotech, Teva The Contender - The IN VIVO Blog, July 7, 2010
"Teva's net margin was 21.8 percent in 2009 and analysts project it will be 25.7 percent this year, compared to 23.6 percent for Big Pharma's group average, according to a consensus analysis by EvaluatePharma..." more...
Big Pharma's Most Feared Competitor - PharmExec.com.com, July 1, 2010
"According to the recent "World Preview Report" by EvaluatePharma, which one of the following will be among the top ten pharmaceutical companies, ranked by sales, in the year 2016: A) Bristol-Myers Squibb, B) Teva, C) Amgen, or D) Genzyme? The answer, you may be surprised to learn, is Teva Pharmaceuticals..." more...
June 2010
Innovaro Facilitates the Licensing of Trojantec Infectious Diseases Technology - MarketWatch, June 10, 2010
"Global sales of vaccines and anti-viral drugs reached $48 billion in 2009 and, according to EvaluatePharma(R), are expected to be $70billion by 2016." more...
Head-to-head trials could threaten Roche Lucentis franchise in AMD - The Pharmaletter, June 1, 2010 [subscription only]
"According to...EvaluatePharma’s EP Vantage, [Roche] could receive a definitive answer in 2011 [about the future of the Lucentis (ranibizumab injection) ophthalmology franchise] as at least half a dozen ongoing head-to-head trials begin to report data. .." more... [subscription only]
May 2010
EvaluatePharma estimates $785 billion worldwide sales in 2016 - Pharmaceutical Commerce, May 28, 2010
"Pharmaceutical companies fared better than predicted in 2009, according to EvaluatePharma’s World Preview 2016. The worldwide market grew 2.6%..." more...
Blockbusters - alive and well - Pharmaceutical Executive Digest Europe, May 26, 2010
"[EvaluatePharma's World Preview 2016]...shows, among other things, that the blockbuster is far from dead..." more...
Study shows impending churn in the pharma industry - Daily News & Analysis, May 7, 2010
"New York-headquartered Pfizer will remain the world’s top pharmaceutical company six years from now...a study titled World Preview 2016 by pharma and biotech industry consulting firm EvaluatePharma reveals..." more...
Who Will Be Pharma's Top Dog in 2016? - Pharmaceutical Technology, May 6, 2010
"The year 2016 will see Pfizer (New York) continue to cling to first place on the Top 10 pharma list, but just barely, with Merck & Co. (Whitehouse Station, NJ) and Novartis (Basel, Switzerland) not far behind. A few major patent decisions or further mega-mergers could topple the pharmaceutical giant from its coveted perch, according to analysis from EvaluatePharma...." more...
Humira to be largest selling drug with $10 bn sales; Teva among top 10 by 2016 - Dances with Shadows - Pill Scribe, May 5, 2010
"Abbott’s Humira to treat rheumatoid arthritis will be the top-selling drug with a sales of about $10.1 billion by the year 2016, according to a new forecast World Preview 2016 report published by EvaluatePharma..." more...
Looking into the future of drug sales - The Day, May 5, 2010
"Projected drug sales compiled by EvaluatePharma...show Pfizer's top medicine (No. 3 worldwide) will be arthritis remedy Enbrel..." more...
Pfizer will reign supreme after “patent cliff,” as Humira kicks Avastin off top spot, says EvaluatePharma - The Pharmaletter, May 4, 2010 [subscription only]
"US drug major Abbott Laboratories’ and Japanese firm Eisai’s rheumatoid arthritis treatment Humira (adalimumab) will replace global behemoth Pfizer’s Lipitor (atorvastatin) as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff, according to the World Preview 2016 report from EvaluatePharma..." more... [subscription only]
What's behind Humira's bullish forecast? - Medical Marketing & Media, May 4, 2010
"According to the forecast, by EvaluatePharma, Humira will become the top-selling anti-TNF - and the world's biggest product - in 2012..." more...
Abbott, Teva Emerge as Winners After Patents Expire - Portfolio.com (blog), May 3, 2010
"...Pfizer will remain the top company for overall drug revenue, while Israeli generics maker is slipping into the top 10, according to EvaluatePharma...." more...
Humira elbows Avastin aside in top-drug ranking - FiercePharma, May 3, 2010
"...Market researchers EvaluatePharma have crunched the numbers on big-drug sales growth, and while their conclusions might not make Roche super-happy, ..." more...
Pharma outlook - 2016 - cafepharma, May 3, 2010
"...In conjunction with the BIO convention, [EvaluatePharma] has made predictions on the pharma landscape for 2016..." more...
Prolia is Most Valuable R&D Asset; Humira is No. 1 Drug - The IN VIVO Blog, May 3, 2010
"Evaluate Pharma is one of numerous pharma consulting firms to publish its own sweep of the biopharma industry in conjunction with BIO..." more...
Prediction: Lipitor to Cede the 'Best-Selling' Crown to Humira - Wall Street Journal (blog), May 3, 2010
"Humira is one of three RA [rheumatoid arthritis] drugs that will make the top ten, says...EvaluatePharma." more...
Abbott's Humira to Top Avastin as Best-Selling Drug - Bloomberg, May 3, 2010
"Revenue from Humira will increase about 9 percent annually to $10.1 billion in 2016 from $5.6 billion in 2009, London-based EvaluatePharma said..." more...
Humira To Be Top World Drug In 2016, Beating Avastin - Wall Street Journal, May 2, 2010 [subscription only]
"...EvaluatePharma predicts US-based Pfizer, through a strategy of mergers and acquisitions including last year's $68 billion merger with Wyeth, will cling to the top spot in prescription sales..." more... [subscription only]
April 2010
Moving to the Next Level in Biomanufacturing - Pharmaceutical Technology, Apr 2, 2010
"...Evaluate Pharma projects that biologics will account for 50% of the top 100 drugs in 2014, compared with 28% in 2008..." more...
March 2010
PPD launches centre of excellence for vaccines, biologics - PharmaTimes, Mar 25, 2010
"According to EvaluatePharma, the compound annual growth rate of biologics is projected at 8.5% from 2008 to 2014, eight to 10 times greater than the growth rate for small-molecule drugs." more...
February 2010
Biopharmaceuticals: saving the future of our industry - Pharmaceutical Technology Europe, Feb 1, 2010
"...market analysis firm EvaluatePharma has predicted that the top six selling drugs of 2014 will be biotech products, compared with only five in 2008 and one in 2000....In a statement, EvaluatePharma added that the "weight of evidence for a shift to biotech products as the industry's growth driver is overwhelming". more...
January 2010
Novo Hopes for a Diabetes Blockbuster - The Burrill Report, January 30, 2010
"During the last 12 months, predictions for 2010 sales of the drug [Victoza] fell to $591 million from original estimates of $951 million as concerns about potential thyroid cancer risks (based on rodent data) came to the fore, according to EvaluatePharma." more...
Archive - 2009Service Update, August 2010
August 19th, 2010: EvaluatePharma's industry coverage has grown further with the addition of 54 new companies.
Service Update, July 2010
July 22nd, 2010: EvaluatePharma's industry coverage has grown further with the addition of 48 new companies.
Service Update, June 2010
June 24th, 2010: EvaluatePharma's industry coverage has grown further with the addition of 51 new companies.
Service Update, May 2010
May 28th, 2010: EvaluatePharma's industry coverage has grown further with the addition of 59 new companies.
Service Update, April 2010
April 29th, 2010: EvaluatePharma's industry coverage has grown further with the addition of 75 new companies.
Service Update, March 2010
March 31st, 2010: EvaluatePharma's industry coverage has grown further with the addition of 52 new companies.
Service Update, February 2010
March 4th, 2010: EvaluatePharma's industry coverage has grown further with the addition of 120 new companies.
Service Update, January 2010
January 14th, 2010: EvaluatePharma's industry coverage has grown further with the addition of 88 new companies...
Service Update, December '09
December 11th, 2009: 73 More Companies added to EvaluatePharma®.
Service Update, November '09
November 11th, 2009: 29 More Companies added to EvaluatePharma®.
Service Update, October '09
October 15th, 2009: 30 More Companies added to EvaluatePharma®.
Service Update, September '09
September 16th, 2009: 45 More Companies added to EvaluatePharma®.
Service Update, August '09
August 20th, 2009: 40 More Companies added to EvaluatePharma®.
Service Update, July '09
July 22nd, 2009: 29 More Companies added to EvaluatePharma®.
Service Update, June '09
June 26th, 2009: 43 More Companies added to EvaluatePharma®.
Service Update, May '09
May 29th, 2009: 25 More Companies added to EvaluatePharma®.
Service Update, May '09
April 30th, 2009: 99 More Companies added to EvaluatePharma®.
Service Update, April '09
April 6th, 2009: More Companies added; Q4 and year-end results published
Service Update, March '09
March 4th, 2009: 175 Companies added; Q4 & year-end results published; more service upgrades
Service Update, Jan '09
January 26, 2009: 189 Private Companies added; new feature - Search by Company location